ArticleInternational journal of clinical pharmacy2026
A novel predictive model for evaluating thrombus regression in postpartum venous thromboembolism patients.
Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionAntithrombotic evaluation of postpartum venous thromboembolism (VTE) after anticoagulant therapy is challenging because of the lack of high-quality clinical evidence.
aimTo identify and validate a machine learning model to predict thrombus regression in postpartum VTE patients.
methodThis study constructed three cohorts of postpartum VTE patients receiving low-molecular-weight heparin (LMWH): retrospective (n = 200), prospective (n = 50), and external (n = 29) cohorts. The main endpoint was imaging-based thrombus regression. Based on clinical guidelines and literature, we screened 16 potential predictors. The retrospective dataset was analyzed using eight machine learning models to predict thrombus regression after anticoagulant therapy. The performance of the model was evaluated by the area under the receiver operating characteristic curve (AUC-ROC), residual analysis, accuracy, sensitivity and specificity. The optimal model was selected based on its comprehensive performance and further validated on the prospective and external cohorts. Model interpretability was analyzed using variable importance and partial dependence plots.
resultsThrombus regression was significantly associated with anti-Xa activity (p = 0.009), antithrombin III levels (p = 0.028), and D-dimer levels (p = 0.024). Of the eight models, the random forest (RF) model demonstrated the best predictive performance, with the AUC-ROC value of 0.831(95%CI 0.696-0.967), accuracy of 0.77, sensitivity of 0.45, specificity of 0.89, and the highest accuracy in predicting thrombus regression events in the prospective (94.29%) and external (90.00%) postpartum VTE datasets. The key predictive variables were anti-Xa activity, antithrombin III levels, D-dimer levels, and body mass index (BMI).
conclusionBased on data from the three cohorts of patients with postpartum VTE, the RF model was identified as the optimal model for predicting thrombus regression events, with anti-Xa activity, antithrombin III levels, D-dimer levels, and BMI serving as key predictors. This study may help assess changes in the thrombotic state of postpartum VTE patients and guide clinical precision medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.